Key Points:
- A coalition of nine health and life science organizations petitioned Treasurer Jim Chalmers for an urgent review of proposed R&D tax changes.
- Industry leaders warn that limiting refundable tax offsets to companies under 10 years old is highly unworkable for medical research.
- The planned reforms will eliminate tax eligibility for critical “supporting” R&D activities such as manufacturing trial batches.
- Surveys reveal that three in four biotechnology and medical technology firms feel worse off under the proposed budget measures.
A coalition of nine leading Australian life sciences organizations has issued an urgent plea to Treasurer Jim Chalmers, warning that proposed changes to the Research and Development Tax Incentive (RDTI) will severely damage the local biotechnology, medical technology, and health technology sectors. The peak bodies representing the country’s high-tech exporters argue that the proposed rules fail to understand the long, expensive reality of medical development. With recent research showing that three in four local biotech firms feel worse off under the proposed changes, the sector warns of a massive brain drain that could force local innovations overseas.
The controversy stems from the federal government’s recent budget proposal to reform the longstanding RDTI, slated to take effect on July 1, 2028. While the government claims the measures will simplify the tax system and better target emerging startups, the changes introduce a highly controversial 10-year age limit on eligibility for the refundable tax offset. Once a company reaches its tenth year of operation, it will no longer qualify for the refundable cash offset, regardless of whether it is generating revenue. Instead, the firm must transition to a non-refundable tax offset.
Life sciences leaders strongly reject the ten-year restriction, pointing to the unique timelines required to bring medical discoveries to patients. According to industry data, developing a new drug or medical device routinely takes between 10 and 17 years to move from initial laboratory research through clinical trials, regulatory approvals, and production scale-up. In a joint petition, the coalition noted that the government’s own national health strategies acknowledge these long horizons. Forcing young, pre-revenue companies off the refundable offset at the ten-year mark ignores the realities of the commercialization pipeline.
In addition to the age cap, the budget plans to eliminate tax eligibility for “supporting” R&D activities. Although the government proposes increasing the offset rate for “core” experimental R&D activities by 4.5 percentage points, industry groups warn that this change is highly counterproductive. In biotechnology, supporting activities—such as manufacturing small batches of a product to run local clinical trials or reviewing medical literature—are completely inseparable from the core research process. Removing tax relief for these auxiliary steps significantly increases the financial risk of conducting clinical trials in Australia.
The scale of the backlash reflects the immense economic importance of the Australian life sciences industry. The sector supports more than 350,000 jobs across nearly 3,000 individual organizations. Since 2016, biotechnology has consistently been Australia’s largest value-adding export industry outside primary industries. According to reporting by Sky News Australia, the planned changes undermine the sector’s long-range investment plans. High-tech executives warn that instead of boosting national productivity as the government hopes, the tax reforms will dry up the early-stage venture capital needed to sustain high-tech jobs.
The R&D tax shake-up does not exist in a vacuum. Industry leaders argue that the new rules represent a “significant triple threat” when combined with proposed changes to capital gains tax (CGT) arrangements. These dual tax reforms threaten to starve startups of crucial seed funding, making it harder for Australian innovators to attract international investment. If local founders face a more punitive tax regime than their competitors in North America or Europe, they are highly likely to relocate their corporate headquarters and intellectual property overseas before launching clinical trials.
The broader budget package includes measures the business community welcomes, such as raising the maximum eligible R&D expenditure threshold from $150 million to $200 million and expanding the turnover limit for the refundable offset from $20 million to $50 million. However, the package also raises the minimum annual R&D expenditure required to qualify for the tax incentive from $20,000 to $50,000. For early-stage university spin-outs and small research teams, this higher floor could lock them out of the program entirely during their most vulnerable initial years.
As peak bodies like AusBiotech and BioMelbourne Network lobby the treasury for an urgent review, the federal government faces a difficult balancing act. Treasurer Jim Chalmers must decide whether to proceed with the controversial reforms or pause to consult further with the country’s most valuable export industries. If the government fails to address the industry’s concerns, Australia risks losing decades of scientific talent, research infrastructure, and high-paying jobs to global competitors who offer far more stable and supportive innovation incentives.
